Culminating 18 months of research, development and testing, OpenClinica will formally unveil a new version of its software package—Version 3.1—at its Global Conference in Boston on May 8-9.
Ben Baumann, OpenClinica’s Director of Business Development, says the conference will feature a number of demonstration sessions designed to give attendees a live, hands-on experience with the new technology.
OpenClinica facilitates the development of new medical treatments by lowering the cost of clinical trials while raising the standards for efficiency and transparency in clinical research.
The OpenClinica Global Conference brings together users, developers, and other stakeholders from the OpenClinica community to share knowledge and best practices. The event features lectures, case studies, tutorials, panel discussions, posters, and technical demonstrations. Participants in the event represent numerous countries including China, Brazil, Germany, India, Denmark, Taiwan, Austria, Switzerland, Argentina, and the United Kingdom. Participants represent biopharmaceutical companies, device companies, contract research organizations, academic centers, and government agencies.
Kenneth A. Getz, Chairman of the Center for Information & Study on Clinical Research Participation CISCRP, and Senior Research Fellow and Assistant Research Professor at the Tufts Center for the Study of Drug Development, will be the conference’s keynote speaker. He will discuss how open source software and open communities can be a solution to challenges facing the pharmaceutical industry.
“The sustainability of drug development desperately depends on new models of innovation,” said Mr. Getz. “Innovative open source projects like OpenClinica hold tremendous promise for addressing this need,” Getz said.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.